This guide outlines model policies for states to consider to rein in drug prices in 2019 and beyond. Those discussed first most directly target drug prices and therefore are likely to have the greatest impact. This piece also cautions against prioritizing approaches to import drugs from Canada, as these policies are less likely to bring savings despite their public appeal.
This advocacy agenda offers options for improving health and health care at the state level during the 2019 session. It includes state policy options to consider in 2019 regarding private insurance coverage, Medicaid, oral health coverage, health equity, prescription drugs, surprise medical bills, and health care value.